T he recognition of antigens or peptides (p) presented on major histocompatibility complex (MHC) molecules (pMHC) by T cells occurs through T-cell receptors (TCRs). The pMHC-TCR interaction represents a critical step in the initiation of most adaptive immune responses (Fig. 1) . The fundamental understanding of the cellular, molecular and biophysical mechanisms underlying the development and function of T cells, which rely heavily on the TCR, have been elucidated over decades primarily through the analyses of immune responses to model antigens and with the use of TCR transgenic systems (such as 2B4, 5c.c7, OT-1 and 2C) in mice [1] [2] [3] [4] [5] . Despite the accrued knowledge, a complete understanding of antigen-specific T-cell responses in humans remains challenging, owing to the many factors that influence the range and identity of the antigens targeted by T cells during infection and disease 6 . Even for well-studied immunological diseases, identifying the antigenic determinants and the relevant antigen-specific T cells accurately is still an ongoing endeavour. In this Perspective, we discuss progress in the study of antigen-specific T-cell responses in several diseases, with emphasis on current methodology for assessing T-cell specificity, and highlight unique challenges for each group of diseases, especially in relation to the use of methods that enable direct identification of the relevant antigen-specific T cells. Since the first description of multimerized pMHC complexes and of their ability to bind to and identify antigen-specific T cells by flow cytometry 7 , much progress has been made in the study of antigen-specific T cells in various disease settings 8, 9 . Throughout this Perspective, we place emphasis on pMHC multimer-based methods, which although not ideal for every situation and not suitable for all types of human leukocyte antigen (HLA, encoding MHC genes in humans), are amenable to multiplexed specificity analysis with an increasingly broad, less biased and more precise view of the antigen-specific T-cell response (Fig. 2) .
Probing T-cell specificity
Applications of antigen-specific T cells and of TCR identification can inform disease management, as demonstrated in cancer with the use of TCR gene-modified T cells 10, 11 , in infectious disease with the adoptive transfer of virus-specific T cells 12, 13 , and in the monitoring of immune tolerance during allergen immunotherapy 14, 15 . Additionally, both functional and phenotypic characteristics of T cells play a critical part in the therapeutic efficacy of adoptive T-cell transfer strategies 16 and vaccination approaches 8, 17 .
T-cell specificity in cancer. Overexpression or de novo expression of proteins is a hallmark of cancer, and such antigens can be prime targets for T-cell recognition. Early studies of T-cell specificity in patients with melanoma identified several T-cell epitopes as potential targets, including antigens associated with melanin production, such as MART-1, GP100 and tyrosinase; later, numerous mutated germline proteins were identified as antigenic targets for T-cell recognition across various tumour types [18] [19] [20] . Both have led to specific -and in some cases successful -therapeutic strategies in the form of vaccination 21 or of adoptive transfer of antigen-specific T cells 10 . Intriguingly, although tumour-infiltrating lymphocytes from patients with melanoma comprise T cells specific for a range of these antigens, a substantial part of the immune reaction against the tumours could not be attributed to the recognition of these shared tumour antigens 22, 23 . Recently, more attention has been drawn to the T-cell recognition of neoepitopes and neoantigens -epitopes and antigens derived from genetic transformations in tumours -as these new sequences are foreign to the immune system. By being simultaneously immunogenic and cancer-specific, in principle neoantigens are ideal targets for highly specific cancer therapies. Several lines of evidence support the importance of such neoantigens in tumour eradication following immune-therapy strategies [24] [25] [26] [27] . However, although tumour mutation load and the predicted number of neoepitopes provide strong correlates of the clinical efficacy of immunotherapy, detecting the T cells that recognize such neoepitopes in large numbers has been challenging. Still, neoepitope-specific T cells can be detected across different cancer types 25, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] , and tumour 'foreignness' seems to be a major driver for the efficacy of the highly promising checkpoint inhibition therapy for cancer 25, 38, 40 . Additionally, although tissue foreignness can arise in many ways, genetic alterations in tumour cells can be easily mapped even at a Adaptive immune responses and immunopathogeneses are based on the ability of T cells to respond to specific antigens. Consequently, understanding T-cell recognition patterns in health and disease involves studying the complexity and genetic heterogeneity of the antigen recognition pathway, which includes both T-cell receptors and the antigen-presentation machinery. In this Perspective, we overview the development and use of technologies for assessing T-cell recognition in a clinical context, and discuss how knowledge of T-cell recognition pathways can be critical before, during and after disease treatment. The ability to assess T-cell-mediated immunity in individual patients during disease progression might enable the identification of patient-specific biomarkers that predict therapeutic efficacy and response. Effective strategies for the complex analysis of T-cell specificity in clinical settings are highly desirable and could complement current approaches for the monitoring of therapy responses.
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Nature Biomedical eNgiNeeriNg personalized level through next-generation sequencing. As a result, T-cell recognition of tumour-specific mutations has been described in multiple cancer types 25, [28] [29] [30] [31] [32] [33] [34] [35] . Gaps in the understanding of neoepitope recognition by T cells in cancer remain wide, however, limiting the clinical potential of neoepitope-specific targeting therapy 27, 41, 42 . Profiling epitope-specific immune responses in cancer is difficult, mostly because of the nature of cancer development and of the co-evolution of cancer cells under immunological surveillance. First, cancer cells are highly heterogeneous within a given cancer lesion, both between individual patients with the same type of cancer, and across different tumour types 43 . As such, the potential antigen repertoire is massive and, to a large extent, patient-specific. These levels of complexity are challenging to encompass, even with newly developed multiplexed T-cell detection technologies 33 . Second, tumour-reactive T cells are often functionally compromised, owing to immunosuppressive signals released by the tumour; consequently, such T cells may be difficult to culture and assess in functional assays 44 . Third, tumour-reactive T cells recognizing self-antigens most often comprise T cells that escaped central-tolerance mechanisms during T-cell development in the thymus, which means that such T cells are likely to express TCRs with low affinity for their cognate pMHC or to recognize peptides with low MHC affinity. The low affinity for pMHC of these T cells means that obtaining strong TCR-pMHC engagement and generating stable pMHC reagents for T-cell assessment is particularly problematic. An additional complication is that tumour-reactive T cells occur mostly at low frequencies, which further hinders their detection and isolation.
T-cell specificity in infectious disease. Detection and characterization of antigen-specific T cells recognizing common viruses has provided important insights into T-cell immunology. Some viruses seem to hijack parts of the immune system by occupying large parts of the T-cell repertoire: for example, > 10% of T cells in circulation seem to be specific to cytomegalovirus (CMV) in seropositive individuals 45, 46 . As CMV is a common and chronic virus (with a prevalence of > 80% at age of 30) 47 , T-cell reactivity to this virus can have considerable impact on immunological ageing and in the ability of the immune system to respond to foreign antigens 48, 49 . In CMV seronegative individuals, other chronic viruses seem to take up great fractions of the T-cell repertoire, albeit not to the same extent as observed for CMV. Thus, CMV infection should be taken into account as a possible confounder in immune therapeutic Virus-specific T cells are generally easier to detect than cancer-specific or autoreactive T cells. In studies of T-cell responses to viral infection, the predefined antigen repertoire encoded by the virus genome determines the specificity of virus-responsive T cells, which are often present in detectable frequencies following infection. Similarly, in chronic viral infections such T cells are detectable through life. Studying virus-specific T cells has led to critical advances in our understanding of T-cell development in response to both acute and chronic antigen exposure [50] [51] [52] . Although many of the best characterized T-cell epitopes are derived from viruses with large genomes such as the Epstein-Barr virus (EBV) or CMV, unbiased screens using multiplexed approaches would be particularly challenging for such pathogens. These epitopes have so far been identified through more conventional epitope-mapping strategies based on large cell numbers or on expanded T-cell lines. These approaches narrow down antigen candidates with peptide libraries in which functional recognition to different peptide pools has been assessed, and positive pools further dissected down to individual peptide level. Large screens using > 10,000 overlapping peptides, as illustrated for CMV 53 , have also been informative in understanding the breadth of T-cell responses in this context. Similarly, large peptide screens have also been performed to identify T-cell epitopes in the context of Mycobacterium tuberculosis (Mtb) infection 54 . However, for pathogens with large genomes such as Mtb, subsets of proteins are typically targeted on the basis of previous knowledge about their relative immunogenicity 55 ; in this case, the use of pMHC multimers (tetramerguided epitope mapping) has also been shown to be productive 56 . Along these lines, in the study of a rotavirus with a moderately sized genome, a large-scale screening using combinatorial, encoded heavy-metal-tagged pMHC tetramers was used to identify new rotavirus epitopes and to compare the profiles of these cells between different donors and tissues 57 . The analysis of numerous EBV-specific T-cell populations has also showed distinct phenotypes of T cells specific for latent versus lytic EBV antigens 57 . pMHC-multimerbased approaches can thus be leveraged in these settings.
T-cell specificity in autoimmunity and allergy. The interrogation of antigen-specific T cells has also been employed in the context of autoimmunity and allergy, albeit later than for other diseases. Autoimmune T cells that recognize endogenous proteins are generated naturally as the process of T-cell development produces cells with random specificities. T cells with high affinity to endogenous pMHC are deleted during T-cell development in the thymus by centraltolerance mechanisms, and any self-reacting cells that escape into circulation are normally kept in check by peripheral-tolerance pathways (for example, pathways involving immune suppression by regulatory T cells). Nevertheless, these checkpoints are not failproof, and autoimmune diseases -characterized by a failure in immune tolerance -are among the most common human disorders, and can affect virtually every tissue. Most autoimmune diseases, including type I diabetes (T1D), rheumatoid arthritis and multiple sclerosis, have genetic associations with the MHC gene family, especially with HLA class-II molecules, clearly indicating an HLA-CD4-T-cell involvement in their pathophysiology (notably, CD8 T-cell recognition has also been shown to be involved in autoimmunity [58] [59] [60] ). Although the targets of these CD4 and CD8 T cells in autoimmunity are mostly unknown, some progress has been made. In patients with T1D, insulin, glutamic acid decarboxylase (GAD) and proinsulin proteins have been described as T-cell targets, and the presence of T cells specific for these proteins is associated with disease development 59, 61, 62 . The antigens targeted by the immune system in autoimmune diseases can also be modified by post-translational modifications to create neoepitopes, to which no immune tolerance is normally generated. This process has been shown to occur in T1D 59, 63 , systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis 60, 64, 65 . How pre-diabetic non-obese diabetic (NOD) mice develop antibodies and effector T cells that react against citrullinated G protein-coupled receptor 78 (GPR78) (ref. 62 ), and the increased T-cell reactivity to citrullinated peptides arising from GAD65 in patients with T1D has been described previously 61 . Also PersPective Nature Biomedical eNgiNeeriNg in T1D patients, an alternative open reading frame was identified within human insulin mRNA encoding a highly immunogenic polypeptide that is targeted by T cells in these patients 58 . A product from alternative splicing has also been shown to be frequently recognized by T cells in cancer 66 . In general, studying T-cell recognition in autoimmune diseases is difficult owing to the lack of defined antigens, the unpredictable nature of dysfunctional self-tolerance, and the intrinsic difficulties in HLA class-II epitope mapping (Box 1). Although for some diseases, such as T1D, tissue-specific targets of T-cell aggression can be predicted, real challenges lie ahead for some inflammatory diseases, for which target epitopes and the role of T-cell antigen-specific activation are more cryptic or may even be triggered without the initial involvement of specific antigens 67 . In the context of allergy, pMHC tetramers, together with an approach named tetramer-guided epitope mapping, have been used to identify several disease-relevant MHC-class-II-restricted antigens 68, 69 . This information has been leveraged in several investigations into the roles of CD4 T cells in modulating the response to various allergens such as nuts, house dust mites and pollen 15, 70, 71 . Some general aspects of T-cell detection challenges in various disease settings are summarized in Table 1 .
Dissecting T-cell specificity
Interrogation of T-cell specificity in a given disease context can be realized by accessing the disease-mediating T cells directly, often by isolating T cells infiltrating the affected tissues 20, 72 . These can be analysed by T-cell cloning or TCR identification and re-expression, often following bulk T-cell expansion to provide sufficient cells to examine their peptide recognition properties. The T-cell specificity is often identified through the recognition of target cells by using complementary DNA libraries to expressed potential antigens, yeast display assays 73, 74 or target cells of disease origin, such as tumour cells. This strategy was applied for the early discovery of tumour antigens 20 ( Fig. 3 , left arm). Alternatively, the specificity and identification of disease-specific T cells can be accomplished through the screening of a set of predicted antigens selected on the basis of available pathophysiology data (Fig. 3 , right arm). Nowadays, this is the most used strategy, given how the screening capacity has improved significantly over the last decade. This strategy has been widely used for the identification of neoepitope-reactive T cells in cancer by screening blood or tumour-infiltrating lymphocytes for the recognition of peptides derived from the tumour mutagenome 30, 31 . The choice of T-cell epitope-mapping strategy will greatly depend on the disease setting ( Table 2) .
Strategies to map the epitope landscape include (but are not limited to) mass-spectrometry-based sequencing of eluted peptides, next-generation-sequencing-based predictions of mutationderived neoepitopes, and yeast display assays (Fig. 3) . Despite ongoing efforts in the development of multiplexed approaches, in many instances the range of possible antigens that can be screened is too large to be examined using synthesized peptides and pMHC multimer libraries. One way to narrow down candidates is to elute peptides from target cells and to use mass spectrometry to sequence these peptides 32, 75, 76 . Notably, the virtual antigen repertoire seems to contain a variety of peptides, such as spliced isoforms, that are currently not covered by these approaches alone 77, 78 . Thus, a combination of experimental techniques such as mass spectrometry, sequencing analyses, proteasomal digestions and other experimental strategies addressing peptide processing, as well as constantly improving prediction analyses, may be necessary to improve the sensitivity of antigen identification.
Challenges in studying the antigen specificity of CD4 T cells. Across various diseases, CD8 T cells are more frequently studied than CD4 T cells because the tools available for analysis and epitope prediction of the former are more robust (Box 1). This inequality
Box 1 | Challenges in studying CD4 T cells with pmHC multimers
Just as CD8 T cells can be identified using MHC class I multimers, CD4 T cells can be labelled using multimers of MHC class II. However, several factors make using MHC-II significantly more challenging than using MHC-I.
MHC-II expression. Whereas most MHC I proteins can be expressed as recombinant proteins in bacteria and refolded in the presence of peptide ligands (or conditional peptide ligands) 85 , the refolding of MHC-II proteins is notoriously inefficient. MHC-II proteins are typically expressed using insect 154 or mammalian 88 expression systems, which are generally more challenging to setup and optimize.
Variable peptide-binding characteristics. Compared with MHC-I proteins, MHC-II proteins have more diverse properties in terms of the binding to peptide ligands. In addition to their wider range of binding motifs, some MHC-II alleles can often bind the same peptides in multiple registers (for instance, different parts of the same peptide being anchored to the MHC) 89, 155 . As a consequence, some alleles require the careful design of tethered peptide ligands and are therefore not amenable to high-throughput production. This seems to be the case especially for human HLA-DP and HLA-DQ proteins (corresponding to mouse I-A) . Some are amenable to peptide exchange (for example, by cleavage and release of tethered CLIP peptide) and may allow for higherthroughput production (as shown for various human HLA-DR alleles and mouse I-E).
Less predictable peptide-binding motifs. Motifs for peptide binding to MHC-I are generally more complex and, therefore, predicting if a given peptide will bind to an MHC-II allele of interest becomes more difficult 156 .
Higher diversity of alleles expressed by human populations. Several MHC-I alleles have conveniently high allele frequencies in well-studied human populations (for instance, the HLA-A*0201 and HLA-A*1101 alleles are expressed by approximately half of Caucasian and Chinese populations, respectively). By contrast, the frequencies of the most common HLA-DR alleles vary widely between human populations, and the expression of any given allele in any given population rarely exceeds 30%.
Low-frequency antigen-specific effector and memory CD4 T cells. Studies of infectious diseases and allergy that used pMHC tetramers to identify antigen-specific CD4 T cells have highlighted how these cells are often found at remarkably low frequencies. The low frequency probably occurs because CD4 T cells seem to target a broader range of peptide antigens, and coincides with CD4 T-cell responses being typically of lower magnitudes in terms of peak frequencies and of the frequencies observed after contraction and memory formation 157, 158 .
More common lower-affinity T cells. Although MHC-I restricted CD8 T cells with low affinities for an antigen have also been reported, low-affinity CD4 T cells are more commonly reported. This may be influenced primarily by the lack of CD4-mediated stabilization of the MHC-II-TCR complex 83, 84 . Low TCR affinity for pMHC II makes multimer staining much less efficient, and in some cases impossible 159, 160 .
PersPective Nature Biomedical eNgiNeeriNg in tool development partly relates to the structural differences between MHC class-I and class-II molecules: MHC-I has a closed conformation, with restricted peptide binding in terms of length and anchor positions 79 , which allows for the more precise prediction of peptide-binding properties 80 ; conversely, MHC-II molecules have an open conformation that allow the peptide to extend to the end of the MHC-II binding groove, making peptide binding less stringent and more challenging to describe and predict, owing to the greater flexibility of the system 81 . MHC multimers can be generated for both MHC-I and II, and can be used for the assessment of both CD8 and CD4 T cells. However, the expression and refolding of MHC-II molecules is more demanding than for MHC-I molecules, and in most cases requires expression and purification from insect or mammalian cells 82 . Additionally, sufficiently strong binding avidity between pMHC-II multimers and CD4 T cells can be difficult to achieve, which may be partially related to the fact that the CD4 co-receptor provides limited support for the pMHC interactions as compared with the contribution of CD8 for pMHC-I interactions 83, 84 . These complications provide additional challenges for T-cell detection technologies (such as fluorescent-labelled MHC multimers) to reach sufficient signal sensitivity and specificity. Also, widely used strategies for the peptide-exchange of MHC-embedded conditional ligands in large libraries of pMHC complexes have so far only been developed for MHC-I (ref. 85 ). The same holds true for dipeptide-mediated-exchange 86 and facilitated-refolding strategies 87 . Analogous approaches for MHC-II based on the expression of MHC with an enzymatically cleavable, tethered CLIP peptide do allow for the relatively high-throughput production of MHC-II multimers, but such approaches seem to only be feasible for some MHC-II alleles (HLA-DR and mouse I-E alleles have been used effectively, but HLA-DP, HLA-DQ and mouse I-A alleles are less amenable to this application) 88, 89 .
Probing antigen specificity with soluble-phase MHC multimers. When candidate target antigens exist, either predicted or experimentally identified, MHC multimer-based strategies enable the efficient assessment of T-cell reactivity using large peptide libraries. Three strategies for the detection of antigen-specific T cells using PersPective Nature Biomedical eNgiNeeriNg soluble-phase MHC multimers are frequently used in epitopediscovery projects.
Fluorescently labelled combinatorially encoded MHC multimers.
Two approaches that involve the combinatorial encoding of fluorescently labelled MHC multimers are based on the assumption that individual T cells in a given population will respond to a single pMHC molecule in a given library. In this context, unique dual-colour 90 or multivalent code 91 are attributed to each pMHC multimer so that T cells binding to that particular pMHC molecule can be identified. When employing a unique dual-colour code, T cells that do not match the pre-defined list of colour combinations are considered to be non-responsive to the given pMHC multimer. This approach, when compared with single-colour fluorescent-labelling methods, lowers the limit of detection (0.002%) and improves the differentiation between background signals and specific pMHC-binding T cells. Despite these differences, peptide sequences with some variation are Nature Biomedical eNgiNeeriNg needed for both methods to minimize cross-recognition within samples. This strategy has been used to dissect T-cell reactivity to 45 different pMHC complexes in a single sample, but recent progress in muliticolour flow cytometry may easily expand the strategy to higher complexity. As the latest flow cytometers allow up to 50 parameters to be detected simultaneously, efforts are underway to characterize and design new fluorescent molecules so as to match this complexity. Nevertheless, not all fluorochromes have sufficient intensity to be used for tagging MHC multimerspecific T cells. With a hypothesized number of 30 different fluorochromes available for tagging MHC multimers, the system using dual-colour codes would allow 420 different T-cell specificities to be analysed in a given sample, which is far beyond what has previously been implemented using this strategy, and represents complexity that will certainly call for enhanced computational analyses of the flow cytometry data 92 . It should be noted that despite improved analytic tools and automated compensation matrices adjusting for spectral overlap between fluorescent molecules, spectral overlap in certain channels will inevitably lead to substantial reductions in signal 93 .
Metal-labelled combinatorially encoded MHC multimers using mass cytometry. Mass cytometry, which employs heavy-metal-ion tags to study cells, has increased the number of labels that can be applied in parallel dramatically when compared with fluorescence flow cytometry [94] [95] [96] . Using ten metal labels in mass cytometry with combinatorial pMHC-tetramer staining in unique combinations of three labels per MHC multimer, 109 antigen-specificities can be screened per sample, with a substantial number of labels still left available for parallel phenotyping and functional analysis of the T cells 57 . By extending this approach with additional metal channels dedicated to pMHC tetramers or by using quadruple combinatorial coding, several hundred tetramers could be used in parallel while still retaining > 20 channels that would be available for profiling of the antigen-specific cells.
The mass-cytometry-based high-dimensional assessment of T-cell phenotype and function has shown that T cells derived from human blood and tissues are remarkably diverse in terms of their protein-expression profiles [97] [98] [99] [100] . High-resolution insight into T-cell profiles is particularly powerful when combined with the ability to discriminate T cells on the basis of antigen specificity. In this way, T cells derived from tiny tissue samples, such as tumour-infiltrates, can be used without the need for in vitro expansion to simultaneously screen for T-cell specificity and to deeply profile the antigenspecific cells detected. Mass cytometry has some disadvantages as a screening platform, namely its low efficiency in cell capture (only 40% of the acquired cells are typically analysed) and the inability to retrieve the analysed cells; however, these limitations are slowly being overcome.
Mass cytometry and the ability to analyse large numbers of proteins at the single-cell level, together with the development of several new high-dimensional data-analysis methods, have led to a greater appreciation of the complexity of immune-cell heterogeneity in circulation and in tissues [97] [98] [99] [100] . In particular, mass spectrometry has been used to reveal the extent of functional heterogeneity of T cells across tissues, as well as how this complexity relates to the expression of various cellular markers such as trafficking receptors [101] [102] [103] . Also, in various disease settings, mass cytometry is being used to profile changes in cellular composition over the course of disease more broadly [104] [105] [106] . The remaining challenge is to understand how T-cell diversity relates to antigen specificities, and how this information can be used to better understand and predict disease outcomes.
DNA-barcode-labelled MHC multimers.
The implementation of DNA barcodes as a new type of label is an additional technique recently reported for detecting T-cell antigen specificities. In this approach, unique DNA barcodes can be applied to MHC multimers to form specific tags for individual pMHC epitopes 33 , leaving aside the need for combinatorial fluorescence or metal labels. Up to 10 10 distinct DNA barcode sequences can be designed, each constituting a unique tag 107 . As a result of this range of possible identifying markers, the number of available labels is no longer a bottleneck as has been the case in previous methods for the high-throughput identification of antigen-specific T cells: > 1,000 specificities can be screened in a single sample, and the readout measures the number of pMHC-TCR interactions rather than the number of specific cells. By taking advantage of a common fluorescent label on all pMHC multimers, the approach enables the estimation of the frequency of specific T cells in a given sample 33 . The DNA-barcode approach has the advantage of being less limited by the problems associated with separation of multimerpositive and multimer-negative cells on the basis of fluorescence signals, and thus presents clear advantages for detecting lowavidity TCR-pMHC interactions, for example as those of tumourassociated antigens 33 . Detection of low-avidity tumour-specific T cells with fluorescence separation is limited by the amount of fluorescently labelled pMHC mutimer binding to their surface, but the use of DNA barcodes overcomes avidity-related issues in the identification of these T cells. Still, the potential of this strategy to identify T-cell specificity as being correlated to disease progression or response to therapy remains unproven. The detection of selfantigens may also be useful in the study of both cancer and autoimmune T-cell recognition in these respective groups of diseases. Of note, the nature of the tag has an ideal structure for combining pMHC binding with sequencing approaches, as the DNA barcode tag can be amplified and revealed in any sequencing platform on adaptation.
Other MHC-multimer-based approaches. In parallel to the development of soluble-phase multimer approaches, several platebound or matrix strategies have also been developed to increase the capacity of pMHC-based screenings.
Protein-based microarrays have been developed and combined with pMHC-based capturing of T cells, with single or multimer pMHC employed either as the plate-bound protein directly responsible for cell capturing [108] [109] [110] [111] [112] [113] [114] or as specific probes associating pMHC molecules to a specific spot on the microarray. However, the spatial separation of T cells may impact the sensitivity of the overall strategy, given that most such approaches seem to be limited by low sensitivity and reproducibility when compared with existing cytometry-based analyses.
Matrix-based approaches developed for the identification of T cells use a set of MHC multimers spread over matrix-defined pools so that no individual MHC multimer is present in all pools. An equal number of cell aliquots, derived from an individual sample, are then stained with each multimer pool. For each pool, TCRβ sequencing is applied to both the MHC multimer-positive and multimer-negative populations after cell sorting. The TCRβ clonotypes that are enriched in the positive population and uniquely identified in pools carrying a given pMHC molecule are then used to reveal the antigen specificities within the sample 115 . A similar approach has been used to identify numerous allergy antigens based on CD4 T-cell recognition 71, 116 .
Detection of T-cell specificity with functional markers. Several techniques have been used to determine the functional capacity of antigen-specific T cells and to identify target-reactive T cells on the basis of a functional readout, including measurements of cytokine release either by intracellular cytokine staining or ELISPOT (Table 2 ). Recent studies are based on the staining of surface markers upregulated by antigen stimulation; for example, CD154 and CD137 have been used to efficiently track Nature Biomedical eNgiNeeriNg antigen-responding T cells in disease settings 29 . However, this strategy does not provide direct information on peptide recognition of the responding T-cell population. Ideally, when antigen-specific T cells are examined using MHC multimer staining, additional functional characterization of the cells should be provided. Unfortunately, T-cell stimulation leads to TCR internalization and, consequently, may reduce or completely impede MHC multimer labelling and invalidate such combined analyses. Information about functional capacity can be essential to understanding the role of pMHC-specific T cells in a given disease setting. For instance, tumour-infiltrating lymphocytes have been described as being specific for both wild-type and mutated pMHCmultimers 30 , as distinct binding of a defined mutated pMHC multimer may not necessarily exclude wild-type reactivity 32 . Therefore, to gain deeper insights into disease-specific T cells in a given patient, current technological developments for large-scale descriptive analyses of T cells by MHC multimer technologies should be followed by the investigation of T-cell function in a defined clinical context. For an in-depth and fully validated characterization of T-cell responses, additional testing systems that allow for functional analyses and deeper phenotyping and RNA sequencing are critical, and may require their combination with TCR isolation and transduction.
understanding antigen recognition
T-cell recognition and killing of target cells presenting non-selfpeptides (epitopes) bound to MHC molecules is mediated by the heterodimeric TCR. The number of possible distinct TCRs (α β TCRs) generated through genetic recombination has been estimated at approximately 10 15 ; however, the number of distinct TCRs in an individual human is probably closer to 10 7 (refs 117, 118 ). Adding to the TCR complexity is the genetic variation in MHC-I loci, which results in a large diversity in MHC expression among individuals. Although TCRs seem to be highly restricted in terms of HLA-recognition as determined by the individual's HLA type 119, 120 , a single T cell is capable of recognizing multiple antigens (estimates suggest that each TCR can recognize up to 10 6 different peptide sequences 74, 121 ). Based on these characteristics, T-cell recognition is a process with a complexity that matches that of intruding pathogens. Hence, strategies that allow coverage of both the complexity of the antigen landscape and the cross-recognition capabilities of a given TCR could reveal new aspects of the relationship between antigen diversity and TCR recognition. Such information might also provide insights into the relationship between infectious agents and autoimmune reactivity, a link that has been suggested for some autoimmune diseases for decades 122 .
Genome-wide epitope mapping and antigen selection. The methods currently available to map antigen specificity on the molecular level are insufficient to match the diversity of immune recognition. Consequently, immune analyses are currently focusing on a panel of model antigens. The identification of disease-relevant targets for immune recognition will greatly enhance the ability to tackle pathogenesis and tissue destruction. Therefore, technologies are needed that extend the state of the art significantly to enable a much more comprehensive assessment of T-cell-mediated immunity.
Although tools for the prediction of peptide binding affinity for MHC have become valuable for predicting peptide presentation 123 , this information only describes part of the potential immunogenicity. Unbiased analyses of peptide presentation and their ability to mount immune responses are needed to enable the prediction of other parameters than MHC binding, which is currently the key component for any such prediction. However, the characteristics of antigen processing are currently not improving the prediction of pMHC presentation. Recent progress has been made in the development of more sensitive mass-spectrometry-based analyses of MHC-embedded peptides 32, 124, 125 . Such strategies, especially when combined with unbiased T-cell analyses, should improve the ability to predict which peptides will be significantly presented at the cell surface, particularly those capable of mounting an immune response.
Improved peptide-MHC affinity prediction tools are of particular interest in the context of personalized neoepitope vaccines 124, 126 . Neoepitopes, defined by the patient's cancer mutagenome, can be formulated into a patient-specific, tumour-targeted vaccine 41 . However, most available vaccines enable the combination of 2-20 different epitopes in their formulations, and hence require precise prediction tools. Currently, limited knowledge is available on the immunogenicity of neoepitopes, and consequently prediction algorithms suffer from low sensitivity of prediction 127, 128 . More comprehensive and unbiased full mutagenome-wide analyses of T-cell recognition would provide valuable data for the improvement of such predictions.
Current tools allow for the screening of T-cell recognition by using up to 1,000 different pMHC complexes in a single sample. For DNA-barcode-labelled MHC multimers, the tagging system may even allow for more comprehensive screenings, as the maximum library size that can be applied for the simultaneous screening of T-cell recognition using this strategy has not yet been reached. Certainly, limitations exist in the ability of a given T cell to reach all possible pMHC complexes in a reaction mixture while avoiding unspecific binding driven by CD8 interactions in conditions of high pMHC multimer concentrations. Microfluidics systems may be of use in enabling these reactions, possibly even allowing for full peptidomics screening.
The combination of T-cell specificity analysis with complex phenotyping and assessment of functional characteristics is also of critical importance. Mass cytometry (cytometry by time-of-flight mass spectrometry, or CyTOF)-based strategies already enable this type of multiparameter analyses, and may even be extended in the future as the number of pMHC multimers integrated into this strategy continues to increase, and as mass cytometry methods improve in terms of throughput, sensitivity and cellular recovery. In parallel, emerging developments in single-cell analyses and index sorting allow for single-cell mRNA expression analyses, whereas protein levels of selected factors can be determined by flow cytometry 129 . More recently, fast, efficient and high-throughput strategies for single-cell analyses, such as the drop-seq approaches 130, 131 , have been developed. In these, antibodies 132, 133 or pMHC molecules 33 may be barcoded with DNA to obtain specific knowledge on protein expression and T-cell specificity while maintaining the information on the embedded mRNA expression (Fig. 3) .
Interrogating the naive T-cell repertoire. As highly multiplexed T-cell detection technologies become increasingly more sensitive, the interrogation of the naive T-cell repertoire in order to understand the potential targets of naive T cells 134 may become possible. The ability to fight infections and the risk of developing autoimmune diseases vary between individuals and change during life. Such variations can be explained partially by the genetic variations in HLA expression, but the repertoire of T-cell specificities plays a clear role in determining the ability of the cells to recognize target cells expressing foreign, endogenous or modified antigens.
Current tools to interrogate the TCR repertoire are immature. New insights into the recognition of the TCR repertoire could significantly improve the ability to design personalized therapies based on individual expression patterns or on the patient's potential to respond to such antigens as determined by their T-cell repertoire. Currently, no techniques exist that enable the interrogation of the naive T-cell repertoire in a comprehensive fashion. It has been shown that the ability of T cells to respond to an antigen challenge is dependent on the frequency of precursor naive T cells capable of recognizing that antigen, and that such measure can PersPective Nature Biomedical eNgiNeeriNg successfully be incorporated in vaccine design, particularly when selecting for epitopes that are most likely to raise immune recognition. Interrogation of naive precursor T-cell frequencies at the individual level is labour intensive and not yet feasible for implementation in patient-tailored therapies. Ongoing initiatives to target neoepitopes in cancer through therapeutic vaccination are currently challenged by the weak prediction of neoepitope immunogenicity. New technologies shedding light on the T-cell repertoire of patients and on their ability to respond to specific antigens would significantly increase the chance of selecting effective vaccination targets (at the epitope level) 28 .
Improved target prediction through TCR profiling. Despite significant improvements in T-cell detection technology, any links between TCR sequence and antigen-recognition profiling are yet to be established. Such interactions are highly complex, and are expected to be extremely challenging to predict. A first step could involve improving the computational models of the TCR-pMHC interaction. In this regard, large libraries of matched pairs of TCR-epitope specificity are required to achieve sufficient insights into TCR-based epitope recognition to empower such computational models and ultimately enable the prediction of epitope-recognition motifs based on TCR sequence. Some progress is being made in this area 135, 136 , and strategies for collection of TCR sequence and antigen specificity at the single-cell level are becoming increasingly more efficient. Also, yeast display of pMHC libraries is being used to improve the understanding of the range of antigens that a given TCR can recognize 73 . Recently, two independent studies demonstrated the feasibility of assessing the peptide-recognition motif of a given TCR and predicted the diversity of peptide restriction 137, 138 . Such analyses could initiate predictions of pMHC restriction based on TCR sequence. Computational models have been developed that enable the prediction of antibody epitopes 139 , which suggests that TCR-based predictions will be possible. Such strategies would provide a whole new dimension to immunological understanding and to the ability to predict T-cell recognition.
T-cell specificity networks. More sophisticated tools can lead to a more complete picture or network structure of how the T-cell repertoires work as a whole, and how stimulation with certain antigens during infection can, potentially, impact self-antigen recognition through complex cross-recognition interactions. The study of these networks will require tools that enable a comprehensive screening for distinct T-cell epitopes and the analyses of additional related recognition patterns. These developments, which will require experiments and computation, will provide landscapes of T-cell recognition patterns associated with the recognition of distinct epitopes. The benefit of identifying such T-cell recognition networks will be an improved understanding of how immune-mediated diseases may co-evolve or impact each other, and how vaccine strategies can be tailored to match individual T-cell repertoire landscapes.
outlook
The strategies mentioned in this Perspective can lead to the generation of valuable data to determine or predict the T-cell responsiveness to a given therapeutic intervention, and hence serve as a biomarker to guide personalized therapeutic decisions. Depending on the disease context and HLA types, a patient-specific selection of targets can be essential. A fully personalized therapeutic strategy is already a reality in the form of neoepitope vaccinations 41 . Additionally, the immunocompetence of patients can be an extremely important factor for disease management, particularly when taking into account age 140 (for example, younger individuals mount stronger immune responses on influenza vaccinations 49 ). Additionally, preexisting immunity should also be taken into account, as CMV infection in a younger individual has also been shown to enhance immune responsiveness to additional infections or vaccination 49 . Immune evaluation, both during and after therapeutic interventions, may guide decision making. For some therapies in current clinical practice, T-cell responses, essential to efficacy, can already be measured. These may serve as a dynamic parameter of response to therapy, allowing for the early assessment of response signs and for the identification of non-responding patients (Fig. 4) .
Our increased knowledge of T-cell recognition and immune regulation is being translated quickly into therapeutic strategies, especially in the areas of cancer therapy. Future challenges lie in defining the efficacy of such strategies based on individual immune responsiveness and, consequently, in tailoring any such strategies to the immune capacity and disease setting of the patient. Efficient approaches to measure immunoresponsiveness can be integrated into clinical practice and enable improved therapy solutions and novel insights into disease development and mechanism. 
